Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()

PURPOSE: Although targeting angiogenesis with tyrosine kinase inhibitors (TKIs) has become standard of care in the treatment of clear cell renal cell carcinoma (RCC), resistance mechanism are not fully understood, and there is a need to develop new therapeutic options overcoming them. METHODS AND MA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Choi, Han-Yong, Kwon, Ghee-Young, Park, Woong Yang, Lee, Jeeyun, Park, Se Hoon
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2017
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358930/
https://ncbi.nlm.nih.gov/pubmed/28325666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2017.01.016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados